Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-134623 · Präparat HOS-097580
Clotrimazole Not studied. Concomitant systemic
use of clotrimazole and boosted
darunavir may increase plasma
concentrations of darunavir and/or
clotrimazole.
Darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage or
colchicine and boosted darunavir an interruption of colchicine
may increase the exposure to treatment is recommended in patients
colchicine. with normal renal or hepatic function
(CYP3A and/ or P-gp inhibition) if treatment with boosted darunavir is
required. For patients with renal or
hepatic impairment colchicine with
boosted darunavir is contraindicated
(see sections 4.3 and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, 8, artemether Cmin ↔ darunavir and
24, 36, 48, and 60 hours artemether Cmax ↓ 18% artemether/lumefantrine can be used
dihydroartemisinin AUC ↓ 18% without dose adjustments; however,
dihydroartemisinin Cmin ↔ due to the increase in lumefantrine
dihydroartemisinin Cmax ↓ 18% exposure, the combination should be
lumefantrine AUC ↑ 175% used with caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and The combination of rifapentine and
Rifapentine rifampicin are strong CYP3A boosted darunavir is not
inducers and have been shown to recommended.
cause profound decreases in
concentrations of other protease The combination of rifampicin and
inhibitors, which can result in boosted darunavir is contraindicated
virological failure and resistance (see section 4.3).
development (CYP450 enzyme
induction). During attempts to
overcome the decreased exposure
by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) clotrimazole (HOS-090574) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 64fdfa97cef778c7193c87ea0168964e1f464c278d0316c8ae901fe34d28a3c8 · Zeichen 40700–43992 im Abschnitt
Wechselwirkungen · Descovy
Descovy 200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-134942 · Präparat HOS-097638
Co-administration of ketoconazole or
itraconazole, which are potent P-gp
inhibitors, is expected to increase
plasma concentrations of tenofovir
alafenamide.
Fluconazole Interaction not studied with either of Dose Descovy according to the
Isavuconazole the components of Descovy. concomitant antiretroviral (see
section 4.2).
Co-administration of fluconazole or
isavuconazole may increase plasma
concentrations of tenofovir
alafenamide.
Antimycobacterials
Rifabutin Interaction not studied with either of Co-administration of Descovy and
Rifampicin the components of Descovy. rifabutin rifampicin, or rifapentine
Rifapentine is not recommended.
Co-administration of rifampicin,
rifabutin, and rifapentine, all of which
are P-gp inducers, may decrease
tenofovir alafenamide plasma
concentrations, which may result in
loss of therapeutic effect and
development of resistance.
Anti-hepatitis C virus medicinal products
Ledipasvir (90 mg once daily)/ Ledipasvir: No dose adjustment of ledipasvir or
sofosbuvir (400 mg once daily), AUC: ↑ 79% sofosbuvir is required. Dose
emtricitabine (200 mg once Cmax: ↑ 65% Descovy according to the
daily)/ tenofovir alafenamide Cmin: ↑ 93% concomitant antiretroviral (see
(10 mg once daily) 3 section 4.2).
Sofosbuvir:
AUC: ↑ 47%
Cmax: ↑ 29%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) sofosbuvir (HOS-108928) ketoconazole (HOS-084513) rifabutin (HOS-086262) ledipasvir (HOS-110493) hepatitis C virus (HOS-108813) itraconazole (HOS-084516) fluconazole (HOS-087945) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 5391e3f045a08ca426387b5308c49acd9a067914739bd44d5f63cff33a3b8f7f · Zeichen 3503–5872 im Abschnitt
Wechselwirkungen · Descovy
Descovy 200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-135011 · Präparat HOS-097638
Co-administration of ketoconazole or
itraconazole, which are potent P-gp
inhibitors, is expected to increase
plasma concentrations of tenofovir
alafenamide.
Fluconazole Interaction not studied with either of Dose Descovy according to the
Isavuconazole the components of Descovy. concomitant antiretroviral (see
section 4.2).
Co-administration of fluconazole or
isavuconazole may increase plasma
concentrations of tenofovir
alafenamide.
Antimycobacterials
Rifabutin Interaction not studied with either of Co-administration of Descovy and
Rifampicin the components of Descovy. rifabutin rifampicin, or rifapentine
Rifapentine is not recommended.
Co-administration of rifampicin,
rifabutin, and rifapentine, all of which
are P-gp inducers, may decrease
tenofovir alafenamide plasma
concentrations, which may result in
loss of therapeutic effect and
development of resistance.
Anti-hepatitis C virus medicinal products
Ledipasvir (90 mg once daily)/ Ledipasvir: No dose adjustment of ledipasvir or
sofosbuvir (400 mg once daily), AUC: ↑ 79% sofosbuvir is required. Dose
emtricitabine (200 mg once Cmax: ↑ 65% Descovy according to the
daily)/ tenofovir alafenamide Cmin: ↑ 93% concomitant antiretroviral (see
(10 mg once daily)3 section 4.2).
Sofosbuvir:
AUC: ↑ 47%
Cmax: ↑ 29%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) sofosbuvir (HOS-108928) ketoconazole (HOS-084513) rifabutin (HOS-086262) ledipasvir (HOS-110493) hepatitis C virus (HOS-108813) itraconazole (HOS-084516) fluconazole (HOS-087945) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 6c687bbb037e1ba31a8849027e7f435533d859237f7a05c8cfb64e0a18ac4d39 · Zeichen 3504–5873 im Abschnitt
Wechselwirkungen · Vemlidy
Vemlidy 25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-135915 · Präparat HOS-097792
6
Medicinal product by Effects on drug levels.a,b Recommendation concerning co-administration
therapeutic areas Mean ratio (90% with Vemlidy
confidence interval) for
AUC, Cmax, Cmin
ANTIDEPRESSANTS
Sertraline Tenofovir alafenamide No dose adjustment of Vemlidy or sertraline is
(50 mg orally, s.d.) ↔ Cmax 1.00 (0.86, 1.16) required.
↔ AUC 0.96 (0.89, 1.03)
Tenofovir alafenamidee
(10 mg orally, q.d.) Tenofovir
↔ Cmax 1.10 (1.00, 1.21)
↔ AUC 1.02 (1.00, 1.04)
↔ Cmin 1.01 (0.99, 1.03)
Sertraline Sertraline
(50 mg orally, s.d.) ↔ Cmax 1.14 (0.94, 1.38)
↔ AUC 0.93 (0.77, 1.13)
Tenofovir alafenamidee
(10 mg orally, q.d.)
ANTIFUNGALS
Itraconazole Interaction not studied. Co-administration is not recommended.
Ketoconazole Expected:
↑ Tenofovir alafenamide
ANTIMYCOBACTERIALS
Rifampicin Interaction not studied. Co-administration is not recommended.
Rifapentine Expected:
↓ Tenofovir alafenamide
Rifabutin Interaction not studied. Co-administration is not recommended.
Expected:
↓ Tenofovir alafenamide
HCV ANTIVIRAL AGENTS
Sofosbuvir (400 mg orally, Interaction not studied. No dose adjustment of Vemlidy or sofosbuvir is
q.d.) Expected: required.
↔ Sofosbuvir
↔ GS-331007
Ledipasvir/sofosbuvir Ledipasvir No dose adjustment of Vemlidy or
(90 mg/400 mg orally, q.d.) ↔ Cmax 1.01 (0.97, 1.05) ledipasvir/sofosbuvir is required.
↔ AUC 1.02 (0.97, 1.06)
Tenofovir alafenamidef ↔ Cmin 1.02 (0.98, 1.07)
(25 mg orally, q.d.)
Sofosbuvir
↔ Cmax 0.96 (0.89, 1.04)
↔ AUC 1.05 (1.01, 1.09)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ketoconazole (HOS-084513) rifabutin (HOS-086262) ledipasvir (HOS-110493) itraconazole (HOS-084516) sertraline (HOS-086247) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-31T09:05:00Z · SHA-256 fe69ec0120bf519ffbfbc733bef6aef6622c9f34191c9918790e7ff2aa064333 · Passage 0d9f2e7c0990a47aa4b75317f58d53bbe06596946d7d0b545b7f11b91b233f82 · Zeichen 3672–5899 im Abschnitt
Wechselwirkungen · Epclusa
Epclusa 400 mg/100 mg film-coated tablets Epclusa 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-136121 · Präparat HOS-097846
6
products with Epclusa is contraindicated (see section 4.3). Medicinal products that are moderate
P-gp inducers and/or moderate CYP inducers (e.g. efavirenz, modafinil, oxcarbazepine or rifapentine)
may decrease sofosbuvir or velpatasvir plasma concentration leading to reduced therapeutic effect of
Epclusa. Co-administration with such medicinal products is not recommended with Epclusa (see
section 4.4). Co-administration with medicinal products that inhibit P-gp or BCRP may increase
sofosbuvir or velpatasvir plasma concentrations. Medicinal products that inhibit OATP, CYP2B6,
CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. Clinically significant
medicinal product interactions with Epclusa mediated by P-gp, BCRP, OATP, or CYP450 inhibitors
are not expected; Epclusa may be co-administered with P-gp, BCRP, OATP and CYP inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) rifapentine (HOS-116386) efavirenz (HOS-087947) oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 904fa254d86a3b1d2f87bd3f541d9ea86fc0eb18f164f596eec4f3f7ee8e755a · Zeichen 1348–2209 im Abschnitt
Wechselwirkungen · Epclusa
Epclusa 400 mg/100 mg film-coated tablets Epclusa 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-136144 · Präparat HOS-097846
10
Medicinal product by Effects on medicinal product levels.
therapeutic areas/Possible Mean ratio (90% confidence interval)a,b
Recommendation concerning
Mechanism of Interaction Active Cmax AUC Cminco-administration with Epclusa
Rifapentine Interaction not studied. Co-administration of Epclusa with
Expected: rifapentine is expected to decrease
↓ Sofosbuvir the concentration of sofosbuvir and
↓ Velpatasvir velpatasvir, leading to reduced
(Induction of P-gp and therapeutic effect of Epclusa.
CYPs) Co-administration is not
recommended (see section 4.4).
HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS
Tenofovir disoproxil Epclusa has been shown to increase tenofovir exposure (P-gp-inhibition). The
fumarate increase in tenofovir exposure (AUC and Cmax) was around 40-80% during co-
treatment with Epclusa and tenofovir disoproxil fumarate/emtricitabine as part of
various HIV regimens.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) rifapentine (HOS-116386) tenofovir disoproxil fumarate (HOS-110471) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage cacf764b7adbcae75239b79c0f2116731d83f63094b15c6b070dbf0cce6cdb7d · Zeichen 15782–17219 im Abschnitt
Wechselwirkungen · Epclusa
Epclusa 200 mg/50 mg coated granules in sachet Epclusa 150 mg/37.5 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 38
HOS-136172 · Präparat HOS-097846
Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP. Velpatasvir is also a
substrate of drug transporter OATP1B. In vitro, slow metabolic turnover of velpatasvir by CYP2B6,
CYP2C8 and CYP3A4 was observed. Medicinal products that are strong inducers of P-gp and/or
strong inducers of CYP2B6, CYP2C8, or CYP3A4 (e.g. carbamazepine, phenobarbital and phenytoin,
rifampicin, rifabutin and St. John’s wort) may decrease plasma concentrations of sofosbuvir or
velpatasvir leading to reduced therapeutic effect of sofosbuvir/velpatasvir. The use of such medicinal
products with Epclusa is contraindicated (see section 4.3). Medicinal products that are moderate
P-gp inducers and/or moderate CYP inducers (e.g. efavirenz, modafinil, oxcarbazepine or rifapentine)
may decrease sofosbuvir or velpatasvir plasma concentration leading to reduced therapeutic effect of
Epclusa. Co-administration with such medicinal products is not recommended with Epclusa (see
section 4.4). Co-administration with medicinal products that inhibit P-gp or BCRP may increase
sofosbuvir or velpatasvir plasma concentrations. Medicinal products that inhibit OATP, CYP2B6,
CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. Clinically significant
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) efavirenz (HOS-087947) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 9aaf624382664712e09a998d5c3447380f0969e14f809738d5faaf0776064425 · Zeichen 713–1967 im Abschnitt
Wechselwirkungen · Epclusa
Epclusa 200 mg/50 mg coated granules in sachet Epclusa 150 mg/37.5 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 42
HOS-136192 · Präparat HOS-097846
(Induction of P-gp and Observed: ↓ ↓
CYPs) Sofosbuvir 0.64 0.76
(0.53, (0.63,
0.77) 0.91)
Rifapentine Interaction not studied. Co-administration of Epclusa with
Expected: rifapentine is expected to decrease
↓ Sofosbuvir the concentration of sofosbuvir and
↓ Velpatasvir velpatasvir, leading to reduced
(Induction of P-gp and therapeutic effect of Epclusa.
CYPs) Co-administration is not
recommended (see section 4.4).
HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS
Tenofovir disoproxil Epclusa has been shown to increase tenofovir exposure (P-gp-inhibition). The
fumarate increase in tenofovir exposure (AUC and Cmax) was around 40-80% during co-
treatment with Epclusa and tenofovir disoproxil fumarate/emtricitabine as part of
various HIV regimens.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) rifapentine (HOS-116386) tenofovir disoproxil fumarate (HOS-110471) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 16490131c8295c1712205ae16bb2a0b4dab8fbcabb7eb6a4006acc2d9e113e32 · Zeichen 15455–16826 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-138466 · Präparat HOS-098200
Darunavir and cobicistat are metabolised by CYP3A. Medicinal products that induce CYP3A activity
would be expected to increase the clearance of darunavir and cobicistat, resulting in lowered plasma
concentrations of darunavir and cobicistat (e.g. efavirenz, carbamazepine, phenytoin, phenobarbital,
rifampicin, rifapentine, rifabutin, St. John’s Wort) (see section 4.3 and interaction table below).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) efavirenz (HOS-087947) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage e345f26efbe9fe3bf51ee2435d2303526ee016e62695b90fc74baf3832b95516 · Zeichen 1633–2031 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-138486 · Präparat HOS-098200
12
ANTIMALARIALS
Artemether/Lumefantrine Based on theoretical considerations Symtuza and
DRV/COBI is expected to increase artemether/lumefantrine can be
lumefantrine plasma used without dose adjustments;
concentrations. however, due to the increase in
(CYP3A inhibition) lumefantrine exposure, the
combination should be used with
caution.
ANTIMYCOBACTERIALS
Rifampicin Based on theoretical considerations The combination of rifampicin
rifampicin is expected to decrease and Symtuza is contraindicated
darunavir and/or cobicistat and/or (see section 4.3).
tenofovir alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction)
Rifabutin Based on theoretical considerations Co-administration of Symtuza
Rifapentine these antimycobacterials are with rifabutin and rifapentine is
expected to decrease darunavir not recommended. If the
and/or cobicistat and/or tenofovir combination is needed, the
alafenamide plasma recommended dose of rifabutin is
concentrations. 150 mg 3 times per week on set
(CYP3A and/or P-gp induction) days (for example
Monday-Wednesday-Friday).
Increased monitoring for rifabutin
associated adverse reactions
including neutropenia and uveitis
is warranted due to an expected
increase in exposure to rifabutin.
Further dose reduction of
rifabutin has not been studied. It
should be kept in mind that the
twice weekly dose of 150 mg may
not provide an optimal exposure
to rifabutin thus leading to a risk
of rifamycin resistance and a
treatment failure. Consideration
should be given to official
guidance on the appropriate
treatment of tuberculosis in HIV
infected patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lumefantrine (HOS-114826) artemether (HOS-116383) rifabutin (HOS-086262) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 37b1a8ed5fbc959e0c62ff07b54b15ba0df2d2ba1c8eeefb033338da5eac50e7 · Zeichen 18477–21949 im Abschnitt
Gegenanzeigen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-138646 · Präparat HOS-098240
Co-administration with the following medicinal products:
- fampridine (also known as dalfampridine);
- carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
- rifampicin, rifapentine;
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole;
- systemic dexamethasone, except as a single dose treatment;
- St John's wort (Hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) dalfampridine (HOS-124191) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 9174ae712b2df8e1079fcece69b45cda4a99f625ece4256ab47b980d2ebdfffe · Zeichen 94–482 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-138703 · Präparat HOS-098240
(induction of CYP3A
enzymes).
Rifapentine/ Dolutegravir ↓ Co-administration may cause significant decreases
Dolutegravir (Not studied) in rilpivirine plasma concentrations. This may
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage d100d4fc0f40378b5dcdb7853334ec03bc9ea2a372cafb6627ca8bc951c55ad8 · Zeichen 24490–24758 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-138704 · Präparat HOS-098240
13
result in loss of therapeutic effect of
Rifapentine/ Rilpivirine ↓ dolutegravir/rilpivirine (induction of CYP3A
Rilpivirine Not studied. Significant enzymes). Co-administration of
decreases in rilpivirine dolutegravir/rilpivirine with rifapentine is
plasma concentrations are contraindicated (see section 4.3).
expected.
Antimalarials
Artemether/ Dolutegravir The combination of dolutegravir/rilpivirine and
Lumefantrine/ (Not studied) artemether/lumefantrine should be used with
Dolutegravir caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 96317d415fed2e0394941b468c93f424ca0fb4f22169acf08db88ee7cc266c64 · Zeichen 24813–25643 im Abschnitt
Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-139283 · Präparat HOS-098314
7
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas/possible levels. co-administration with Biktarvy
mechanism of interaction Mean percent change in AUC,
Cmax, Cmin
Rifapentine Interaction not studied with any of Co-administration is not
the components of Biktarvy. recommended.
(Induction of CYP3A and P-gp) Co-administration of rifapentine
may decrease bictegravir and
tenofovir alafenamide plasma
concentrations.
HIV-1 antiviral agents
Atazanavir (300 mg once daily), Bictegravir: Co-administration is not
Cobicistat (150 mg once daily), AUC: ↑ 306% recommended.
Bictegravir1 Cmax: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) cobicistat (HOS-088111) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 06e656ca252deb09a53e5d53bdf0294c8504ffa0ce5a8b2c8efa0e1ab80d7d25 · Zeichen 5735–6773 im Abschnitt
Gegenanzeigen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-141142 · Präparat HOS-098610
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers
is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur,
which may decrease the effectiveness of Delstrigo (see sections 4.4 and 4.5). These medicinal
products include, but are not limited to the following:
• carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• rifampicin, rifapentine
• St. John’s wort (Hypericum perforatum)
• mitotane
• enzalutamide
• lumacaftor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) carbamazepine (HOS-085618) mitotane (HOS-112479) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) enzalutamide (HOS-116829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage fe61ee953492515bc94a98680d46a2de4cd17d7726126b16b4443bead6cd1ea8 · Zeichen 94–635 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-141188 · Präparat HOS-098610
9
Recommendation concerning
Medicinal product by Effects on medicinal product levels co-administration with
therapeutic area geometric mean ratio (90 % CI)* doravirine/lamivudine/tenofovir
disoproxil
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
disoproxil. Co-administration is
rifapentine
contraindicated.
Expected:
doravirine
(Induction of CYP3A)
If doravirine/ lamivudine/
doravirine
tenofovir disoproxil is co-
AUC 0.50 (0.45, 0.55)
administered with rifabutin, a
Cmax 0.99 (0.85, 1.15)
rifabutin 100 mg dose of doravirine should
C24 0.32 (0.28, 0.35)
(300 mg QD, be taken daily, approximately 12 h
(Induction of CYP3A)
doravirine 100 mg SD) after dose of
doravirine/lamivudine/tenofovir
disoproxil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) rifabutin (HOS-086262) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage ba9413c43f7fef50dc125660e229e1f0062f7d1c7d65f3b1dc7048fb90dddc08 · Zeichen 12432–14140 im Abschnitt
Gegenanzeigen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-141246 · Präparat HOS-098618
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers
is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur,
which may decrease the effectiveness of Pifeltro (see sections 4.4 and 4.5). These medicinal products
include, but are not limited, to the following:
• carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• rifampicin, rifapentine
• St. John’s wort (Hypericum perforatum)
• mitotane
• enzalutamide
• lumacaftor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) carbamazepine (HOS-085618) mitotane (HOS-112479) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) enzalutamide (HOS-116829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage e5fda511a0b33458147c32c880ed181b94fa7af09e5760fffbe53c8a96721df5 · Zeichen 93–634 im Abschnitt
Wechselwirkungen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-141259 · Präparat HOS-098618
5
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic area levels geometric mean ratio co-administration with
(90 % CI)* doravirine
Anticonvulsants
carbamazepine Interaction not studied.
oxcarbazepine
Co-administration is
phenobarbital Expected:
contraindicated.
phenytoin doravirine
(Induction of CYP3A)
Antidiabetics
metformin metformin
(1 000 mg SD, AUC 0.94 (0.88, 1.00) No dose adjustment is required.
doravirine 100 mg QD) Cmax 0.94 (0.86, 1.03)
Interaction not studied.
canagliflozin
Expected:
liraglutide No dose adjustment is required.
↔ canagliflozin
sitagliptin
↔ liraglutide
↔ sitagliptin
Antidiarrhoeals
Interaction not studied. Co-administration should be
avoided. If co-administration
Expected: cannot be avoided, one tablet of
telotristat ethyl
↓ doravirine doravirine should be taken twice
(Induction of CYP3A) daily (approximately 12 hours
apart).
Antigout and uricosuric agents
Interaction not studied. Co-administration should be
avoided. If co-administration
Expected: cannot be avoided, one tablet of
lesinurad
↓ doravirine doravirine should be taken twice
(Induction of CYP3A) daily (approximately 12 hours
apart).
Antimycobacterials
Single dose rifampicin doravirine
(600 mg SD, AUC 0.91 (0.78, 1.06)
doravirine 100 mg SD) Cmax 1.40 (1.21, 1.63)
C24 0.90 (0.80, 1.01)
Co-administration is
Multiple dose rifampicin doravirine contraindicated.
(600 mg QD, AUC 0.12 (0.10, 0.15)
doravirine 100 mg SD) Cmax 0.43 (0.35, 0.52)
C24 0.03 (0.02, 0.04)
(Induction of CYP3A)
Interaction not studied.
Co-administration is
rifapentine Expected:
contraindicated.
doravirine
(Induction of CYP3A)
doravirine If doravirine is co-administered
rifabutin AUC 0.50 (0.45, 0.55) with rifabutin, the doravirine dose
(300 mg QD, Cmax 0.99 (0.85, 1.15) should be increased to 100 mg
doravirine 100 mg SD) C24 0.32 (0.28, 0.35) twice daily (approximately
(Induction of CYP3A) 12 hours apart).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): canagliflozin (HOS-128091) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) lesinurad (HOS-141154) telotristat ethyl (HOS-141158) liraglutide (HOS-121332) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) sitagliptin (HOS-117222) phenytoin (HOS-084531) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage b6c007477c17e1b76ceb7164860101b6c785fb58cc8d8fa8c9e4cb468184eaeb · Zeichen 5245–9123 im Abschnitt
Gegenanzeigen · Vocabria
400 mg Vocabria 400 mg prolonged-release suspension for injection 600 mg Vocabria 600 mg prolonged-release suspension for injection · Abschnitt 4.3 · PDF-Seite 7
HOS-143406 · Präparat HOS-099004
Concomitant use with rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin or
phenobarbital (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T14:50:00Z · SHA-256 5a6802905e0f35577ea123d161d3a8ece2c09d33762d2d6c349b5a0a60e5d7b9 · Passage eef0fa8db44ee623516470760372a10d7225315ab23b657881dc728b07785ed6 · Zeichen 93–214 im Abschnitt
Gegenanzeigen · Vocabria
Vocabria 30 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 30
HOS-143448 · Präparat HOS-099004
Concomitant use with rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin or
phenobarbital (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T14:50:00Z · SHA-256 5a6802905e0f35577ea123d161d3a8ece2c09d33762d2d6c349b5a0a60e5d7b9 · Passage eef0fa8db44ee623516470760372a10d7225315ab23b657881dc728b07785ed6 · Zeichen 93–214 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.